Invesco India Pharma and Healthcare Fund - Direct Plan - Growth
Invesco Asset Management Company Pvt Ltd. · Direct Plan · Growth
Fund overview
0.50% on or before 3M, NIL after 3M
Returns & rankings
| Period | Fund Returns | Category Avg. | Rank | VS Category |
|---|---|---|---|---|
| … | ||||
Green = fund outperformed the category average for that period; red = underperformed. Periods under 1 year always show absolute (non-annualised) returns. Past performance does not guarantee future returns.
Return calculator
One-time investment
₹1,000
| Over the past | Total investment | Would've become | Returns |
|---|---|---|---|
| 1 Year | ₹1,000 | — | — |
| 3 Years | ₹1,000 | — | — |
| 5 Years | ₹1,000 | — | — |
Historical returns aren't available in the current data feed yet — projections will appear once the returns API is live. Mutual fund investments are subject to market risks.
Holdings
13 securitiesTop 10 holdings make up 84.9% of the portfolio.
| Security | Sector | Market Cap | Weight |
|---|---|---|---|
| Triparty Repo | Cash/Deposits/Margins/Treps/Repo/Swaps | — | 20.56% |
| Max Healthcare Institute Ltd | Healthcare Services | Mid Cap | 9.58% |
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals & Biotechnology | Large Cap | 8.99% |
| SAI Life Sciences Ltd | Pharmaceuticals & Biotechnology | Small Cap | 8.63% |
| Apollo Hospitals Enterprises Ltd | Healthcare Services | Large Cap | 8.03% |
| Manipal Health Enterprises Ltd | Healthcare Services | Mid Cap | 7.98% |
| Divi'S Laboratories Ltd | Pharmaceuticals & Biotechnology | Large Cap | 7.85% |
| Global Health Ltd | Healthcare Services | Small Cap | 7.00% |
| Dr. Agarwals Health Care Ltd | Healthcare Services | Small Cap | 6.32% |
| Corona Remedies Ltd | Pharmaceuticals & Biotechnology | Small Cap | 6.13% |
Portfolio Allocation
Equity / Debt / Cash
Total Value
₹436 Cr
Market Cap Split
Total Value
100%
Equity sector allocation
Total Value
₹379 Cr
Exit load, stamp duty & tax
07-Sep-26
0.50% on or before 3M, NIL after 3M
0.005% (from July 1st, 2020)
Taxation depends on the fund category and holding period. Consult the scheme document or a tax advisor for details.
Risk & Performance Ratios (1Y)
| Standard Deviation | -- |
| Beta | -- |
| Sharpe Ratio | -- |
| Sortino Ratio | -- |
| Treynor Ratio | -- |
| Jensen's Alpha | -- |
| Information Ratio | -- |
| R-Squared | -- |
| Max Drawdown | -- |
| Upside Capture | -- |
| Downside Capture | -- |
Fund management
Scheme Details
Investment objective
To Generate Long Term Capital Appreciation By Investing Predominantly In Equity And Equity Related Securities Of The Companies In Pharmaceuticals, Healthcare And Allied Sectors. There Is No Assurance That The Investment Objective Of The Scheme Will Be Achieved.
Fund house
Invesco Asset Management Company Pvt Ltd.
Frequently asked questions
What is the NAV of Invesco India Pharma and Healthcare Fund - Direct Plan - Growth?
The NAV of Invesco India Pharma and Healthcare Fund - Direct Plan - Growth is ₹8.97 as of 21 Oct 2026. NAV is updated at the end of every trading day.
How much expense ratio is charged by Invesco India Pharma and Healthcare Fund - Direct Plan - Growth?
The expense ratio charged by Invesco India Pharma and Healthcare Fund - Direct Plan - Growth is 0.59%.
What is the Min. SIP of Invesco India Pharma and Healthcare Fund - Direct Plan - Growth?
The minimum SIP investment in Invesco India Pharma and Healthcare Fund - Direct Plan - Growth is ₹100 per month.
What is the Min. Lumpsum of Invesco India Pharma and Healthcare Fund - Direct Plan - Growth?
The minimum lumpsum investment in Invesco India Pharma and Healthcare Fund - Direct Plan - Growth is ₹1,000.
What is the Exit Load of Invesco India Pharma and Healthcare Fund - Direct Plan - Growth?
The exit load for Invesco India Pharma and Healthcare Fund - Direct Plan - Growth is: 0.50% on or before 3M, NIL after 3M
.svg){kind=small}